Exhibit 10.2

 

Amendment No. 1 to the

Restricted Stock Agreement
Granted Under 2004 Stock Incentive Plan, as amended

 

This Amendment No. 1, effective as of November 4, 2009,  is to the Restricted
Stock Agreement made on March 7, 2007 between Momenta Pharmaceuticals, Inc., a
Delaware corporation (the “Company”), and Steven Brugger (the “Participant”).

 

For valuable consideration, receipt of which is acknowledged, the parties hereto
agree to amend the Agreement as follows.

 

2.             SECTION 2(A) OF THE AGREEMENT IS HEREBY DELETED AND REPLACED WITH
THE FOLLOWING:

 

One hundred thousand (100,000) Shares shall vest and become free from forfeiture
under Section 2(c) hereof and become free from the transfer restrictions in
Section 3 hereof on the date that the Company (or any of the Company’s partners
or collaborators) commercially launches M-Enoxaparin in the United States,
provided, that such commercial launch occurs on or before March 7, 2011 and
provided further, that such Shares shall only vest pursuant to this
Section 2(a) if the Participant is employed by the Company on the date of such
vesting event. For the purpose of this Section and vesting hereunder,
“commercial launch” shall not be deemed to have occurred earlier than ten
(10) days after the marketing approval of M-Enoxaparin in the United States by
the United States Food and Drug Administration.

 

Except as explicitly set forth herein, all other terms and conditions of the
Agreement remain in full force and effect.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first above written.

 

 

MOMENTA PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ Richard P. Shea

 

 

Richard P. Shea

 

 

 

 

 

/s/ Steven B. Brugger

 

Steven B. Brugger

 

--------------------------------------------------------------------------------